Zeb Irfan, Ahmadi Naser, Nasir Khurram, Kadakia Jigar, Larijani Vahid Nabavi, Flores Ferdinand, Li Dong, Budoff Matthew J
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA.
J Cardiovasc Dis Res. 2012 Jul;3(3):185-90. doi: 10.4103/0975-3583.98883.
Aged garlic extract (AGE) and coenzyme Q10 (CoQ10) have been shown to affect multiple cardiovascular risk factors. The current study evaluates the effect of AGE combined with CoQ10 on inflammatory markers and progression of coronary atherosclerosis compared with placebo.
In this placebo-controlled, double-blind, randomized trial, 65 intermediate risk firefighters (age 55 ± 6 years) were treated with a placebo capsule or a capsule containing AGE and CoQ10 (AGE+CoQ10, 1200 and 120 mg, respectively) daily for 1 year. All participants underwent coronary artery calcium (CAC) scanning and C-reactive protein (CRP) at baseline and at 12 months. At 1 year, mean CAC progression was significantly lower in AGE+CoQ10 (32 ± 6 vs. 58 ± 8, P = 0.01) than placebo. Similarly, CRP were significantly decreased in AGE+CoQ10 compared with placebo (-0.12 ± 0.24 vs. 0.91 ± 0.56 mg/L, P < 0.05). After adjustment for age, gender, conventional cardiac risk factors, and statin therapy, AGE+CoQ10 was associated with 3.99 fold (95% 1.3-12.2, P = 0.01) lack of CAC progression compared with the placebo.
AGE+CoQ10 are associated with beneficial effects on inflammatory markers and reduced progression of coronary atherosclerosis.
已有研究表明， aged garlic extract (AGE) 和辅酶Q10 (CoQ10) 可影响多种心血管危险因素。本研究旨在评估AGE联合CoQ10与安慰剂相比，对炎症标志物和冠状动脉粥样硬化进展的影响。
在这项安慰剂对照、双盲、随机试验中，65名中度风险消防员（年龄55±6岁）每天接受安慰剂胶囊或含有AGE和CoQ10的胶囊（分别为1200和120毫克）治疗，为期1年。所有参与者在基线和12个月时均接受冠状动脉钙化（CAC）扫描和C反应蛋白（CRP）检测。1年后，AGE+CoQ10组的平均CAC进展显著低于安慰剂组（32±6 vs. 58±8，P = 0.01）。同样，与安慰剂相比，AGE+CoQ10组的CRP显著降低（-0.12±0.24 vs. 0.91±0.56毫克/升，P < 0.05）。在调整年龄、性别、传统心脏危险因素和他汀类药物治疗后，与安慰剂相比，AGE+CoQ10组缺乏CAC进展的可能性高3.99倍（95% 1.3 - 12.2，P = 0.01）。
AGE+CoQ10对炎症标志物具有有益作用，并可减少冠状动脉粥样硬化的进展。
